Newsroom
latest news from ose
and across our portfolio
Featured News
All News
Portfolio NewsOMass TherapeuticsCEO Ros Deegan appointed to UK Prime Minister's Business CouncilPortfolio NewsOMass TherapeuticsOMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business OfficerPortfolio NewsOMass TherapeuticsOMass Therapeutics Adds Mark Namchuk, PhD to Scientific Advisory BoardPortfolio NewsOMass TherapeuticsOMass Therapeutics Announces Appointment of New Board Chair and Series B ExtensionPortfolio NewsOMass TherapeuticsOMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio ProgressPortfolio NewsOMass TherapeuticsPublication in Nature Chemistry between Omass Therapeutics and co-founder Dame Carol Robinson demonstrates the benefits of native mass spectrometry in the interrogation of target ecosystems and drug discoveryPortfolio NewsOMass TherapeuticsOMass Therapeutics appoints Dr Jon Roffey as Vice President, Head of Medicinal ChemistryPortfolio NewsOMass TherapeuticsOMass Therapeutics raises $100 million in Series B financing to progress drug pipeline in immunology and rare diseasesPortfolio NewsOMass TherapeuticsPublication in Nature by OMass Founder, Professor Dame Carol Robinson, shows power of native mass spectrometry in drug discoveryPortfolio NewsOMass TherapeuticsOMass Therapeutics establishes scientific advisory board of leading expertsPortfolio NewsOMass TherapeuticsOmass Therapeutics OdyssION™ drug discovery platform makes progress in drugging the undruggablePortfolio NewsOMass TherapeuticsOMass Therapeutics unveils rich drug discovery pipeline targeting intractable or inadequately drugged membrane and complex-bound proteins